Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections.

CASE SERIES SUMMARY: This case series describes five cats with cutaneous adverse events after subcutaneous administration of frunevetmab, a felinised anti-nerve growth factor monoclonal antibody, including histopathological findings in one case. All cats displayed moderate to severe pruritus resulting in self-trauma to the neck and/or head, causing lesions ranging from superficial dermatitis to alopecia and ulcerations. There were no reactions at the injection sites. In one cat, clinical signs developed after the second frunevetmab dose the cat received, with no reaction noted after the first dose. For the remaining cats, clinical signs were observed after their first dose of frunevetmab. The onset of the first episode of pruritus and self-trauma was 3-18 days after the most recent frunevetmab injection. Three cats had one or more additional frunevetmab injections after the original adverse event and all had subsequent reactions. Subsequent reactions were either similar in time frame or occurred more rapidly, with similar or more severe pruritus compared with the original reactions. Treatments and outcomes varied between cases. RELEVANCE AND NOVEL INFORMATION: Frunevetmab is a novel, monthly injectable monoclonal antibody for the management of pain associated with osteoarthritis in cats. This is the first published report detailing the nature of cutaneous adverse events associated with this treatment, and the first report of the histopathological findings.

Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report.

Canine cutaneous epitheliotropic T-cell lymphoma (CETL) is associated with a poor prognosis and without consistently beneficial treatment options. This case report describes a 9-year-old Staffordshire bull terrier with CETL treated with oclacitinib (0.7 mg/kg twice daily), resulting in partial remission that was maintained for three months. Further studies are warranted.

Le lymphome cutané T épithéliotrope canin (CETL) est associé à un pronostic faible et sans option thérapeutique bénéfique constante. Ce cas clinique décrit un Staffordshire bull-terrier de 9 ans avec CETL traité avec oclacitinib (0,7 mg/kg deux fois par jour), résultant en une rémission partielle qui s'est maintenue trois mois. Des études supplémentaires sont nécessaires.

El linfoma epiteliotrópico cutáneo de células T canino (CETL) se asocia con un mal pronóstico y sin opciones de tratamiento consistentemente beneficiosas. Este informe de caso describe un Staffordshire bull terrier de 9 años con CETL tratado con oclacitinib (0,7 mg/kg dos veces al día), lo que resultó en una remisión parcial que se mantuvo durante tres meses. Se necesitan más estudios.

O linfoma epiteliotrópico canino de células T (CETL) está associado a um mau prognóstico e sem opções de tratamento consistentemente benéficas. Este relato de caso descreve um Staffordshire bull terrier de 9 anos de idade com CETL tratado com oclacitinib (0,7 mg/kg duas vezes ao dia), resultando em remissão parcial que foi mantida por três meses. Mais estudos são necessários.

Carbon dioxide laser surgery for chronic proliferative and obstructive otitis externa in 26 dogs.

BACKGROUND: Some dogs with chronic otitis externa (OE) develop proliferation of the tissues surrounding the opening of the external ear canal, resulting in obstruction. Traditionally total ear canal ablation with bulla osteotomy (TECABO) has been recommended. OBJECTIVES: To evaluate the efficacy of a novel treatment using carbon dioxide (CO2 ) laser surgery and to describe the histopathological features of chronic proliferative and obstructive OE. ANIMALS: Twenty-six dogs were included, 16 with bilateral and 10 with unilateral disease (42 ears were treated). Dogs with nonpatent horizontal ear canal or macroscopic calcification of the ear canal were excluded. For histopathological evaluation, tissue samples were collected from 11 dogs (17 ears). METHODS AND MATERIALS: Hyperplastic tissue around the canal opening and within the vertical ear canal was dissected and ablated using a CO2 laser. Biopsy samples were evaluated for sebaceous and ceruminous gland hyperplasia, epidermal hyperplasia, inflammation and fibrosis. RESULTS: Following CO2 laser surgery there was a good or excellent outcome with substantial resolution of proliferative changes in 39 of 42 ears from 24 of 26 dogs. One surgery was sufficient in 21 dogs and three dogs had two surgeries. Two dogs had recurrence of proliferative tissue after one surgery and underwent TECABO. Two dogs had no recurrence of proliferative tissue after surgery, yet had persistent luminal infection and underwent TECABO. The remainder of the dogs were effectively medically managed long-term following surgery. Histologically, eight ears had a predominantly sebaceous gland response, three had a predominantly ceruminous response and six had a mixed glandular pattern. Epidermal hyperplasia, inflammation and fibrosis varied from mild to severe. CONCLUSIONS AND CLINICAL RELEVANCE: Carbon dioxide laser surgery is an effective treatment of proliferative OE causing obstruction of the ear canal opening and vertical canal, and should be considered as an alternative to TECABO whenever possible.